Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2192-3183
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Drug-induced thrombocytopenia associated with trastuzumab in a patient with HER2-positive recurrent gastric cancer ; day:2 ; month:11 ; year:2021 ; pages:1-4
International Cancer Conference journal ; (2.11.2021), 1-4
- Creator
-
Takano, Yuko
Furune, Satoshi
Miyai, Yuki
Morita, Sachi
Inoue, Megumi
Shimokata, Tomoya
Sugishita, Mihoko
Mitsuma, Ayako
Maeda, Osamu
Ando, Yuichi
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s13691-021-00520-z
- URN
-
urn:nbn:de:101:1-2022011621182836798827
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:31 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Takano, Yuko
- Furune, Satoshi
- Miyai, Yuki
- Morita, Sachi
- Inoue, Megumi
- Shimokata, Tomoya
- Sugishita, Mihoko
- Mitsuma, Ayako
- Maeda, Osamu
- Ando, Yuichi
- SpringerLink (Online service)
Other Objects (12)
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer
Predictors of trastuzumab-induced cardiotoxicity among racially and ethnically diverse patients with HER2-positive breast cancer
Severe Thrombocytopenia from Trastuzumab and Pertuzumab Combination Therapy in a Patient with HER2-Positive Metastatic Rectal Cancer
Vasculogenic mimicry is associated with trastuzumab resistance of HER2-positive breast cancer
Panitumumab-Associated Drug-Induced Immune Thrombocytopenia in a Patient with Colorectal Cancer
NT-proBNP correlates with LVEF decline in HER2-positive breast cancer patients treated with trastuzumab
Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy
Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer
Long-term response to trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal adenocarcinoma
CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
Trastuzumab Deruxtecan: A Quantum Leap in HER2‑Positive Breast Cancer
Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
Correction to: Population pharmacokinetics of PF‑05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin®) in patients with HER2‑positive metastatic breast cancer